Cancer Therapy

PharmaGap cancer drug effective using systemic (intra-peritoneal) administration

Published in Drug Week, October 27th, 2006

PharmaGap Inc. (GAP) released the results of new animal tests indicating effectiveness of its lead cancer drug, PhGalpha1 which confirm that PharmaGap compounds may be deliverable to select cancers via the IP route, an accepted mode of delivery in the clinic.

This finding represents a significant advance by PharmaGap in the development of a commercializable cancer drug.

Dr. David Barnes, M.D., drug development advisor to the company, said, "This result is a major success for PharmaGap's development program for PhGalpha1. We now see that the compounds can be administered in a clinically relevant manner to a living animal subject, a well-recognized...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2006-10-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry